Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) advises that Mr. Ajay Nair has been appointed to the new role of General Manager – Global Sales & Marketing.
Appointment of GM – Global Sales & Marketing Read More »
22-27 October 2021
ACG 2021 Annual Scientific Meeting, American College of Gastroenterology
Mandalay Bay, Las Vegas
Resonance Health will be attending the ACG 2021 Annual Scientific Meeting and Postgraduate Course hosted by the American College of Gastroenterology on 22-27 October 2021.
ACG 2021 Annual Scientific Meeting Read More »
Burjeel Medical City opens Thalassemia Center to help children with Thalassemia
VPS Healthcare’s premium medical facility, Burjeel Medical City at Mohammed Bin Zayed City, Abu Dhabi, has opened a Thalassemia Center to offer exclusive treatment for children diagnosed with the illness.
Resonance Health News – June 2021 Read More »
Resonance Health is delighted to provide you with our latest customer newsletter, where you can find an update on all our latest acitvities. To read the newsletter please click here
Resonance Health News – June 2021 Read More »
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021.
Appointment Of Chief Financial Officer & Company Secretary Read More »
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to advise that Mr. Nick Allan has accepted an offer of employment with the Resonance Health group as Chief Financial Officer & Company Secretary (“CFO & Co Sec”) commencing on 31 May 2021.
Appointment of Chief Financial Officer & Company Secretary Read More »
Cardiac T1 Mapping and ECV Phantom (T1MES) What is T1MES? The T1 Mapping and ECV Standardization Program (“T1MES”) was developed to explore T1 mapping quality assurance on 1.5 and 3T magnets across numerous CMR centres worldwide. This program progressed with the development and regulatory approval of a T1MES phantom. The T1MES Phantom was originally designed by
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).
Hepafat-ai Receives Ce Marking Read More »
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received CE mark for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).
HepaFat-AI Receives CE Marking Read More »
Resonance Health Ltd (ASX: RHT) (“Resonance Health” or “Company”) is pleased to announce that it has received Australian Therapeutic Goods Administration (“TGA”) approval for HepaFat-AI, the Company’s fully automated artificial intelligence (“AI”) software that assesses liver fat (the “Device”).
HepaFat-AI Receives TGA Approval Read More »
INVESTORS
SUPPORT
PATIENTS
PHYSICIANS